Clinical Scorecard: Evaluating the Effectiveness of the Prostate Health Index Combined with Multiparametric MRI for Prostate Cancer Diagnosis Across Varying PSA Levels and Its Role in Clinical Decision-Making

At a Glance

Key Highlights

• PSA alone has limited sensitivity and specificity, leading to overdiagnosis and unnecessary biopsies.
• PHI is FDA-approved for PCa diagnosis in patients with PSA 2.0-10.0 ng/ml and predicts grade reclassification in active surveillance.
• mpMRI provides detailed anatomical and staging information, aiding in risk stratification and biopsy targeting.

Guideline-Based Recommendations

Diagnosis

• Use PHI combined with mpMRI to improve detection of clinically significant prostate cancer (csPCa).
• Classify mpMRI results using PI-RADS version 2; scores 1-2 considered negative, ≥3 warrant biopsy consideration.
• Perform 12-core systematic biopsy with additional cognitive MRI fusion-guided targeted biopsies for suspicious lesions.

Management

• Incorporate PHI and mpMRI findings to guide biopsy decisions and reduce unnecessary procedures.
• Use ISUP grading system (2014) to classify biopsy specimens; ISUP ≥ 2 defines clinically significant PCa.

Monitoring & Follow-up

• Apply PHI for monitoring men on active surveillance to detect grade reclassification.
• Use mpMRI for ongoing assessment of tumor progression and treatment response.

Risks

• Recognize biopsy-associated complications and aim to minimize unnecessary biopsies through improved diagnostic accuracy.
• Consider potential false negatives and positives inherent to PSA and mpMRI, especially near diagnostic thresholds.

Patient & Prescribing Data

Men aged ≥50 years with PSA levels between 4-10 ng/ml undergoing PCa diagnostic evaluation.

Combining PHI with mpMRI reduces repeat biopsy necessity and improves detection of clinically significant prostate cancer compared to PSA and mpMRI alone.

Clinical Best Practices

• Exclude patients on 5-α reductase inhibitors or with recent prostate procedures or infections to avoid confounding PSA/PHI results.
• Use standardized laboratory methods (Beckman Coulter DxI 800) and imaging protocols (Siemens 3.0T mpMRI) with expert double-blinded radiologist interpretation.
• Apply structured consensus for mpMRI interpretation discrepancies to ensure diagnostic consistency.
• Utilize ROC curve analysis and Youden index to determine optimal diagnostic cutoffs for PHI and mpMRI.

References

• Global burden of prostate cancer
• PSA limitations and controversies
• FDA approval of PHI for PCa diagnosis
• PRECISION study on mpMRI
• Gnanapragasam et al. on PHI and mpMRI combination
• ISUP 2014 Gleason grading system
• DeLong test for AUC comparison